and in turn promote the proliferation of tumor cells. In this study, high-risk HPV was also detected. The rate of HPV infection was significantly greater in the CIN group than in www.selleckchem.com/products/PD-0332991.html the healthy control group (P < 0.05), though no differences were seen between the CIN and CC groups (P > 0.05). We also screened the hyper lesion of the cervix correlated with detection of HPV and found that the omission diagnostic rate was very low. Conclusion In summary, IGFBP-5 was highly expressed in CIN, and it may participate as a tumor suppressor in the occurrence and development of cervical lesions. Down-regulation of IGFBP-5 expression was closely related
to CC infiltration, metastasis, and differentiation, whereas cFLIP was highly expressed in CC. The interaction of these two effects may promote the progression of CC. Further study is required to confirm the roles played by these two proteins in the development of these diseases. Analysis of IGFBP-5 and cFLIP expression levels, may be useful tools for clinical diagnosis and differential diagnosis of CIN and cervical cancer. Acknowledgements This work was supported by the National Nature Science Foundation of China (No. 30772327), Shandong Provincial science and technology research projects funding (No. 2008GG10002052) References 1. Firth SM, Baxter RC: Cellular actions of the insulin-like
growth factor binding proteins. Endocr Rev 2002, 23 (6) : 824–854.CrossRefPubMed 2. Miyatake T, Ueda Y, Nakashima R, Yoshino K, Kimura T, Murata PAK5 T,
Nomura T, Fujita M, Buzard GS, Enomoto T: Down-regulation Transmembrane Transporters inhibitor of insulin-like growth factor binding protein-5 (IGFBP-5): novel marker for cervical carcinogenesis. Int J Cancer 2007, 120 (10) : 2068–2077.CrossRefPubMed 3. Beattie J, Allan GJ, Lochrie JD, Flint DJ: Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006, 395 (1) : 1–19.CrossRefPubMed 4. Cobb LJ, Salih DA, Gonzalez I, Tripathi G, Carter EJ, Lovett F, Holding C, Pell JM: Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J Cell Sci 2004, 117 (Pt 9) : 1737–1746.CrossRefPubMed 5. Richman C, Baylink DJ, Lang K, Dony C, Mohan S: Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 1999, 140 (10) : 4699–4705.CrossRefPubMed 6. Butt AJ, Dickson KA, Jambazov S, Baxter RC: Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005, 146 (7) : 3113–3122.CrossRefPubMed 7. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, et al.: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388 (6638) : 190–195.CrossRefPubMed 8.